Synaffix B.V.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Apr 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for Enzymes for trimming of glycoproteins (US 11,713,453) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 2 fees due Jun 26 to 29, 2027 · next Jun 26
- 2 fees due Oct 9 to 16, 2027 · next Oct 9
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
- Oct 13 US 12,758,645 Antibody-Conjugates for Targeting of Tumours Expressing Carcinoembyronic Antigen
- 1 term has ended since Aug 22, 2026
- Sep 11 US 10,072,096 Modified Glycoprotein, Protein-Conjugate and Process for the Preparation Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,222,940 | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions In force · High confidence | In force | High confidence | |
| US 10,239,807 | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions In force · High confidence | In force | High confidence | |
| US 11,358,921 | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions In force · High confidence | In force | High confidence | |
| US 12,180,145 | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions In force · High confidence | In force | High confidence | |
| US 9,504,758 | Modified antibody, antibody-conjugate and process for the preparation thereof In force · USPTO record | In force | USPTO record | |
| US 10,745,488 | Modified antibody, antibody-conjugate and process for the preparation thereof In force · USPTO record | In force | USPTO record | |
| US 10,266,502 | Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne In force · USPTO record | In force | USPTO record | |
| US 11,168,085 | Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne In force · USPTO record | In force | USPTO record | |
| US 12,084,448 | Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne In force · USPTO record | In force | USPTO record | |
| US 9,636,421 | Sulfamide linker, conjugates thereof, and methods of preparation In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 29: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 1 abandoned · 12 no status recorded
Showing 1 to 10 of 24, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/245,164 | Jun 20, 2025 | No status recorded | |
| 19/184,240 | Apr 21, 2025 | No status recorded | |
| 19/052,069 | Feb 12, 2025 | No status recorded | |
| 18/974,659 | Dec 9, 2024 | No status recorded | |
| 18/955,142 | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions | Nov 21, 2024 | Pending |
| 18/892,270 | Antibody-Conjugates for Targeting of Tumours Expressing TROP-2 | Sep 20, 2024 | Pending |
| 18/609,949 | Mar 19, 2024 | Pending | |
| 18/213,151 | Glycan-Conjugated Antibodies Binding to Fc-Gamma Receptor | Jun 22, 2023 | Pending |
| 18/320,403 | Tyrosine-Based Antibody Conjugates | May 19, 2023 | Pending |
| 18/849,558 | Mar 23, 2023 | No status recorded |
10 of 24 applications shown.
Pro members see all 24 published applications.